Zhang Beibei, Wang Junxue, Xu Wensheng, Wang Lei, Ni Wu
Onkologie. 2010;33(10):537-9. doi: 10.1159/000319696. Epub 2010 Sep 10.
The anti-CD20 monoclonal antibody rituximab has been used extensively in the treatment of B-cell lymphoma. However, several studies reported hepatitis B virus (HBV) reactivation after rituximab administration. The majority of these cases have been described in chronic carriers of HBV, whereas reactivation in occult hepatitis B carriers is relatively rare. We report a fatal case of fulminant hepatitis B that occurred in a B-cell lymphoma patient with occult hepatitis B after rituximab-containing chemotherapy, which raised the necessity of antiviral prophylaxis in this setting.
抗CD20单克隆抗体利妥昔单抗已广泛用于治疗B细胞淋巴瘤。然而，多项研究报告了利妥昔单抗给药后乙型肝炎病毒（HBV）再激活的情况。这些病例大多发生在HBV慢性携带者中，而隐匿性乙型肝炎携带者的再激活相对少见。我们报告了1例在接受含利妥昔单抗化疗后发生暴发性乙型肝炎的致死病例，该患者为隐匿性乙型肝炎的B细胞淋巴瘤患者，这凸显了在此情况下进行抗病毒预防的必要性。
